Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 211

1.

Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis.

Phelps R, Winston JA, Wynn D, Habek M, Hartung HP, Havrdová EK, Markowitz GS, Margolin DH, Rodriguez CE, Baker DP, Coles AJ.

Mult Scler. 2019 Apr 15:1352458519841829. doi: 10.1177/1352458519841829. [Epub ahead of print]

PMID:
30986126
2.

Real-Life Outcome in Multiple Sclerosis in the Czech Republic.

Kobelt G, Jönsson L, Pavelcova M, Havrdová EK.

Mult Scler Int. 2019 Feb 18;2019:7290285. doi: 10.1155/2019/7290285. eCollection 2019.

3.

A Serial 10-Year Follow-Up Study of Atrophied Brain Lesion Volume and Disability Progression in Patients with Relapsing-Remitting MS.

Zivadinov R, Horakova D, Bergsland N, Hagemeier J, Ramasamy DP, Uher T, Vaneckova M, Havrdova E, Dwyer MG.

AJNR Am J Neuroradiol. 2019 Mar;40(3):446-452. doi: 10.3174/ajnr.A5987. Epub 2019 Feb 28.

PMID:
30819766
4.

Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.

Brown JWL, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, Girard M, Duquette P, Trojano M, Lugaresi A, Bergamaschi R, Grammond P, Alroughani R, Hupperts R, McCombe P, Van Pesch V, Sola P, Ferraro D, Grand'Maison F, Terzi M, Lechner-Scott J, Flechter S, Slee M, Shaygannejad V, Pucci E, Granella F, Jokubaitis V, Willis M, Rice C, Scolding N, Wilkins A, Pearson OR, Ziemssen T, Hutchinson M, Harding K, Jones J, McGuigan C, Butzkueven H, Kalincik T, Robertson N; MSBase Study Group.

JAMA. 2019 Jan 15;321(2):175-187. doi: 10.1001/jama.2018.20588.

5.

Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study.

Nguyen AL, Havrdova EK, Horakova D, Izquierdo G, Kalincik T, van der Walt A, Terzi M, Alroughani R, Duquette P, Girard M, Prat A, Boz C, Sola P, Ferraro D, Lugaresi A, Lechner-Scott J, Barnett M, Grand'Maison F, Grammond P, Ramo-Tello C, Turkoglu R, McCombe P, Pucci E, Trojano M, Granella F, Spitaleri D, Van Pesch V, Soysal A, Oreja-Guevara C, Verheul F, Vucic S, Hodgkinson S, Slee M, Ampapa R, Prevost J, Menoyo JLS, Skibina O, Solaro C, Olascoaga J, Shaw C, Madsen KG, Naidoo K, Hyde R, Butzkueven H, Jokubaitis V; MSBase Study Group.

Mult Scler Relat Disord. 2019 Feb;28:235-243. doi: 10.1016/j.msard.2019.01.003. Epub 2019 Jan 3.

PMID:
30623864
6.

Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study.

Jensen PEH, Warnke C, Ingenhoven K, Piccoli L, Gasis M, Hermanrud C, Fernandez-Rodriguez BM, Ryner M, Kramer D, Link J, Ramanujam R, Auer M, Buck D, Grummel V, Bertotti E, Fissolo N, Oliver-Martos B, Nytrova P, Khalil M, Guger M, Rathmaier S, Sievers-Stober C, Lindberg RLP, Hässler S, Bachelet D, Aktas O, Donnellan N, Lawton A, Hemmer B, Havrdova EK, Kieseier B, Hartung HP, Comabella M, Montalban X, Derfuss T, Sellebjerg F, Dönnes P, Pallardy M, Spindeldreher S, Broët P, Deisenhammer F, Fogdell-Hahn A, Sorensen PS; ABIRISK Consortium.

J Neuroimmunol. 2019 Jan 15;326:19-27. doi: 10.1016/j.jneuroim.2018.11.002. Epub 2018 Nov 7.

PMID:
30447419
7.

Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study.

Lorscheider J, Kuhle J, Izquierdo G, Lugaresi A, Havrdova E, Horakova D, Hupperts R, Duquette P, Girard M, Prat A, Grand'Maison F, Grammond P, Sola P, Ferraro D, Trojano M, Ramo-Tello C, Lechner-Scott J, Pucci E, Solaro C, Slee M, Van Pesch V, Sanchez Menoyo JL, van der Walt A, Butzkueven H, Kappos L, Kalincik T; MSBase Study Group.

Eur J Neurol. 2019 Feb;26(2):363-370. doi: 10.1111/ene.13824. Epub 2018 Nov 2.

PMID:
30298572
8.

Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study.

Wray S, Havrdova E, Snydman DR, Arnold DL, Cohen JA, Coles AJ, Hartung HP, Selmaj KW, Weiner HL, Daizadeh N, Margolin DH, Chirieac MC, Compston DAS.

Mult Scler. 2018 Oct 5:1352458518796675. doi: 10.1177/1352458518796675. [Epub ahead of print]

PMID:
30289355
9.

Do eyes with and without optic neuritis in multiple sclerosis age equally?

Lizrova Preiningerova J, Grishko A, Sobisek L, Andelova M, Benova B, Kucerova K, Havrdova EK.

Neuropsychiatr Dis Treat. 2018 Sep 5;14:2281-2285. doi: 10.2147/NDT.S169638. eCollection 2018.

10.

Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.

Cohen JA, Comi G, Arnold DL, Bar-Or A, Selmaj KW, Steinman L, Havrdová EK, Cree BA, Montalbán X, Hartung HP, Huang V, Frohna P, Skolnick BE, Kappos L; RADIANCE Trial Investigators.

Mult Scler. 2018 Jul 25:1352458518789884. doi: 10.1177/1352458518789884. [Epub ahead of print]

PMID:
30043658
11.

Reply to: Comment on Y.D. Fragoso et al.: "Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod" [Mult. Scler. Relat. Disord. (2017)].

Fragoso YD, Spelman T, Boz C, Alroughani R, Lugaresi A, Vucic S, Butzkueven H, Terzi M, Havrdova E, Horakova D, Granella F, Olascoaga J, Menoyo JLS, Pucci E, Barnett M, Brooks JBB, Haartsen J; Lymphopenia and Efficacy of Fingolimod MSBase sub-study Investigators.

Mult Scler Relat Disord. 2018 May;22:166. doi: 10.1016/j.msard.2018.02.025. Epub 2018 Feb 24. No abstract available.

PMID:
29807821
12.

Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year employment status in multiple sclerosis patients.

Kadrnozkova L, Vaneckova M, Sobisek L, Benova B, Kucerova K, Motyl J, Andelova M, Novotna K, Lizrova Preiningerova J, Krasensky J, Havrdova E, Horakova D, Uher T.

J Neurol Sci. 2018 May 15;388:87-93. doi: 10.1016/j.jns.2018.02.045. Epub 2018 Mar 6.

PMID:
29627038
13.

No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a.

Havrdová E, Arnold DL, Bar-Or A, Comi G, Hartung HP, Kappos L, Lublin F, Selmaj K, Traboulsee A, Belachew S, Bennett I, Buffels R, Garren H, Han J, Julian L, Napieralski J, Hauser SL, Giovannoni G.

Mult Scler J Exp Transl Clin. 2018 Mar 12;4(1):2055217318760642. doi: 10.1177/2055217318760642. eCollection 2018 Jan-Mar.

14.

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.

Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D; ASCEND investigators.

Lancet Neurol. 2018 May;17(5):405-415. doi: 10.1016/S1474-4422(18)30069-3. Epub 2018 Mar 12.

PMID:
29545067
15.

Establishing pathological cut-offs for lateral ventricular volume expansion rates.

Dwyer MG, Hagemeier J, Bergsland N, Horakova D, Korn JR, Khan N, Uher T, Medin J, Silva D, Vaneckova M, Havrdova EK, Zivadinov R.

Neuroimage Clin. 2018 Feb 7;18:494-501. doi: 10.1016/j.nicl.2018.02.009. eCollection 2018.

16.

Management of multiple sclerosis patients in central European countries: current needs and potential solutions.

Berger T, Adamczyk-Sowa M, Csépány T, Fazekas F, Hojs Fabjan T, Horáková D, Illes Z, Klimová E, Leutmezer F, Rejdak K, Rozsa C, Šega Jazbec S, Szilasiová J, Turčáni P, Vachová M, Vécsei L, Havrdová E.

Ther Adv Neurol Disord. 2018 Feb 22;11:1756286418759189. doi: 10.1177/1756286418759189. eCollection 2018. Review.

17.

Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome.

Matute-Blanch C, Villar LM, Álvarez-Cermeño JC, Rejdak K, Evdoshenko E, Makshakov G, Nazarov V, Lapin S, Midaglia L, Vidal-Jordana A, Drulovic J, García-Merino A, Sánchez-López AJ, Havrdova E, Saiz A, Llufriu S, Alvarez-Lafuente R, Schroeder I, Zettl UK, Galimberti D, Ramió-Torrentà L, Robles R, Quintana E, Hegen H, Deisenhammer F, Río J, Tintoré M, Sánchez A, Montalban X, Comabella M.

Brain. 2018 Apr 1;141(4):1085-1093. doi: 10.1093/brain/awy021.

PMID:
29452342
18.

Survey of diagnostic and treatment practices for multiple sclerosis (MS) in Europe. Part 2: Progressive MS, paediatric MS, pregnancy and general management.

Fernández O, Delvecchio M, Edan G, Fredrikson S, Giovannoni G, Hartung HP, Havrdova E, Kappos L, Pozzilli C, Soerensen PS, Tackenberg B, Vermersch P, Comi G.

Eur J Neurol. 2018 May;25(5):739-746. doi: 10.1111/ene.13581. Epub 2018 Feb 28.

PMID:
29356206
19.

ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis.

Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hartung HP, Havrdova E, Hemmer B, Kappos L, Liblau R, Lubetzki C, Marcus E, Miller DH, Olsson T, Pilling S, Selmaj K, Siva A, Sorensen PS, Sormani MP, Thalheim C, Wiendl H, Zipp F.

Mult Scler. 2018 Feb;24(2):96-120. doi: 10.1177/1352458517751049. Epub 2018 Jan 20.

PMID:
29353550
20.

ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis.

Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hartung HP, Havrdova E, Hemmer B, Kappos L, Liblau R, Lubetzki C, Marcus E, Miller DH, Olsson T, Pilling S, Selmaj K, Siva A, Sorensen PS, Sormani MP, Thalheim C, Wiendl H, Zipp F.

Eur J Neurol. 2018 Feb;25(2):215-237. doi: 10.1111/ene.13536. Epub 2018 Jan 19. Erratum in: Eur J Neurol. 2018 Mar;25(3):605.

PMID:
29352526
21.

Unmet needs, burden of treatment, and patient engagement in multiple sclerosis: A combined perspective from the MS in the 21st Century Steering Group.

Members of the MS in the 21st Century Steering Group:, Rieckmann P, Centonze D, Elovaara I, Giovannoni G, Havrdová E, Kesselring J, Kobelt G, Langdon D, Morrow SA, Oreja-Guevara C, Schippling S, Thalheim C, Thompson H, Vermersch P, Aston K, Bauer B, Demory C, Giambastiani MP, Hlavacova J, Nouvet-Gire J, Pepper G, Pontaga M, Rogan E, Rogalski C, van Galen P, Ben-Amor AF.

Mult Scler Relat Disord. 2018 Jan;19:153-160. doi: 10.1016/j.msard.2017.11.013. Epub 2017 Nov 21.

22.

Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod.

Fragoso YD, Spelman T, Boz C, Alroughani R, Lugaresi A, Vucic S, Butzkueven H, Terzi M, Havrdova E, Horakova D, Granella F, Olascoaga J, Sánchez-Menoyo JL, Pucci E, Barnett M, Brooks JBB, Haartsen J; Lymphopenia and Efficacy of Fingolimod MSBase sub-study Investigators.

Mult Scler Relat Disord. 2018 Jan;19:105-108. doi: 10.1016/j.msard.2017.11.018. Epub 2017 Nov 22.

PMID:
29182993
23.

Gray matter atrophy patterns in multiple sclerosis: A 10-year source-based morphometry study.

Bergsland N, Horakova D, Dwyer MG, Uher T, Vaneckova M, Tyblova M, Seidl Z, Krasensky J, Havrdova E, Zivadinov R.

Neuroimage Clin. 2017 Nov 5;17:444-451. doi: 10.1016/j.nicl.2017.11.002. eCollection 2018.

24.

Pathological cut-offs of global and regional brain volume loss in multiple sclerosis.

Uher T, Vaneckova M, Krasensky J, Sobisek L, Tyblova M, Volna J, Seidl Z, Bergsland N, Dwyer MG, Zivadinov R, De Stefano N, Sormani MP, Havrdova EK, Horakova D.

Mult Scler. 2019 Apr;25(4):541-553. doi: 10.1177/1352458517742739. Epub 2017 Nov 16.

PMID:
29143562
25.

Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program.

Havrdova E, Cohen JA, Horakova D, Kovarova I, Meluzinova E.

Ther Clin Risk Manag. 2017 Oct 16;13:1423-1437. doi: 10.2147/TCRM.S143509. eCollection 2017. Review.

26.

Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis.

Rose JW, Giovannoni G, Wiendl H, Gold R, Havrdová E, Kappos L, Selmaj KW, Zhao J, Riester K, Tsao LC, Greenberg SJ.

Mult Scler Relat Disord. 2017 Oct;17:32-40. doi: 10.1016/j.msard.2017.06.006. Epub 2017 Jun 19.

PMID:
29055471
27.

Towards personalized therapy for multiple sclerosis: prediction of individual treatment response.

Kalincik T, Manouchehrinia A, Sobisek L, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, Izquierdo G, Lugaresi A, Girard M, Prat A, Duquette P, Grammond P, Sola P, Hupperts R, Grand'Maison F, Pucci E, Boz C, Alroughani R, Van Pesch V, Lechner-Scott J, Terzi M, Bergamaschi R, Iuliano G, Granella F, Spitaleri D, Shaygannejad V, Oreja-Guevara C, Slee M, Ampapa R, Verheul F, McCombe P, Olascoaga J, Amato MP, Vucic S, Hodgkinson S, Ramo-Tello C, Flechter S, Cristiano E, Rozsa C, Moore F, Luis Sanchez-Menoyo J, Laura Saladino M, Barnett M, Hillert J, Butzkueven H; MSBase Study Group.

Brain. 2017 Sep 1;140(9):2426-2443. doi: 10.1093/brain/awx185.

PMID:
29050389
28.

Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE.

Cohan S, Kappos L, Giovannoni G, Wiendl H, Selmaj K, Havrdová EK, Rose J, Greenberg S, Phillips G, Ma W, Wang P, Lima G, Sabatella G.

Mult Scler. 2017 Oct 1:1352458517735190. doi: 10.1177/1352458517735190. [Epub ahead of print]

29.

Toxocara spp. seronegativity in Czech patients with early form of multiple sclerosis - clinically isolated syndrome.

Posová H, Hrušková Z, Havrdová E, Kolářová L.

Epidemiol Mikrobiol Imunol. Fall 2017;66(3):124-127.

PMID:
28948806
30.

Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis.

Kalincik T, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, Lechner-Scott J, Lugaresi A, Prat A, Girard M, Duquette P, Grammond P, Solaro C, Grand'Maison F, Hupperts R, Prevost J, Sola P, Ferraro D, Terzi M, Butler E, Slee M, Kermode A, Fabis-Pedrini M, McCombe P, Barnett M, Shaw C, Hodgkinson S, Butzkueven H; MSBase Study Group.

Mult Scler. 2018 Oct;24(12):1617-1626. doi: 10.1177/1352458517728812. Epub 2017 Aug 31. Erratum in: Mult Scler. 2017 Dec;23(14):NP1.

PMID:
28857680
31.

Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.

Coles AJ, Cohen JA, Fox EJ, Giovannoni G, Hartung HP, Havrdova E, Schippling S, Selmaj KW, Traboulsee A, Compston DAS, Margolin DH, Thangavelu K, Chirieac MC, Jody D, Xenopoulos P, Hogan RJ, Panzara MA, Arnold DL; CARE-MS II and CAMMS03409 Investigators.

Neurology. 2017 Sep 12;89(11):1117-1126. doi: 10.1212/WNL.0000000000004354. Epub 2017 Aug 23.

32.

Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy.

Havrdova E, Arnold DL, Cohen JA, Hartung HP, Fox EJ, Giovannoni G, Schippling S, Selmaj KW, Traboulsee A, Compston DAS, Margolin DH, Thangavelu K, Rodriguez CE, Jody D, Hogan RJ, Xenopoulos P, Panzara MA, Coles AJ; CARE-MS I and CAMMS03409 Investigators.

Neurology. 2017 Sep 12;89(11):1107-1116. doi: 10.1212/WNL.0000000000004313. Epub 2017 Aug 23. Erratum in: Neurology. 2018 Apr 17;90(16):755.

33.

Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS.

Lorscheider J, Jokubaitis VG, Spelman T, Izquierdo G, Lugaresi A, Havrdova E, Horakova D, Trojano M, Duquette P, Girard M, Prat A, Grand'Maison F, Grammond P, Pucci E, Boz C, Sola P, Ferraro D, Spitaleri D, Lechner-Scott J, Terzi M, Van Pesch V, Iuliano G, Bergamaschi R, Ramo-Tello C, Granella F, Oreja-Guevara C, Butzkueven H, Kalincik T; MSBase Study Group.

Neurology. 2017 Sep 5;89(10):1050-1059. doi: 10.1212/WNL.0000000000004330. Epub 2017 Aug 9.

34.

Peripheral blood lymphocytes immunophenotyping predicts disease activity in clinically isolated syndrome patients.

Posová H, Horáková D, Čapek V, Uher T, Hrušková Z, Havrdová E.

BMC Neurol. 2017 Jul 28;17(1):145. doi: 10.1186/s12883-017-0915-1.

35.

Neurological software tool for reliable atrophy measurement (NeuroSTREAM) of the lateral ventricles on clinical-quality T2-FLAIR MRI scans in multiple sclerosis.

Dwyer MG, Silva D, Bergsland N, Horakova D, Ramasamy D, Durfee J, Vaneckova M, Havrdova E, Zivadinov R.

Neuroimage Clin. 2017 Jun 19;15:769-779. doi: 10.1016/j.nicl.2017.06.022. eCollection 2017.

36.

New insights into the burden and costs of multiple sclerosis in Europe: Results of the Czech Republic.

Havrdova E, Kobelt G, Berg J, Capsa D, Gannedahl M, Doležal T; European Multiple Sclerosis Platform.

Mult Scler. 2017 Aug;23(2_suppl):41-52. doi: 10.1177/1352458517708117.

PMID:
28643584
37.

A Novel Semiautomated Pipeline to Measure Brain Atrophy and Lesion Burden in Multiple Sclerosis: A Long-Term Comparative Study.

Uher T, Krasensky J, Vaneckova M, Sobisek L, Seidl Z, Havrdova E, Bergsland N, Dwyer MG, Horakova D, Zivadinov R.

J Neuroimaging. 2017 Nov;27(6):620-629. doi: 10.1111/jon.12445. Epub 2017 May 2.

PMID:
28464417
38.

Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review.

Merkel B, Butzkueven H, Traboulsee AL, Havrdova E, Kalincik T.

Autoimmun Rev. 2017 Jun;16(6):658-665. doi: 10.1016/j.autrev.2017.04.010. Epub 2017 Apr 17. Review.

39.

Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis.

Signori A, Izquierdo G, Lugaresi A, Hupperts R, Grand'Maison F, Sola P, Horakova D, Havrdova E, Prat A, Girard M, Duquette P, Boz C, Grammond P, Terzi M, Singhal B, Alroughani R, Petersen T, Ramo C, Oreja-Guevara C, Spitaleri D, Shaygannejad V, Butzkueven H, Kalincik T, Jokubaitis V, Slee M, Fernandez Bolaños R, Sanchez-Menoyo JL, Pucci E, Granella F, Lechner-Scott J, Iuliano G, Hughes S, Bergamaschi R, Taylor B, Verheul F, Edite Rio M, Amato MP, Sajedi SA, Majdinasab N, Van Pesch V, Sormani MP, Trojano M.

Mult Scler. 2018 Apr;24(5):642-652. doi: 10.1177/1352458517703800. Epub 2017 Apr 6.

PMID:
28382837
40.

"No evident disease activity": The use of combined assessments in the management of patients with multiple sclerosis.

Giovannoni G, Tomic D, Bright JR, Havrdová E.

Mult Scler. 2017 Aug;23(9):1179-1187. doi: 10.1177/1352458517703193. Epub 2017 Apr 6. Review.

41.

Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies.

Havrdova E, Giovannoni G, Gold R, Fox RJ, Kappos L, Phillips JT, Okwuokenye M, Marantz JL.

Eur J Neurol. 2017 May;24(5):726-733. doi: 10.1111/ene.13272. Epub 2017 Mar 22.

42.

MxA mRNA decrease preceding NAb detection in IFNβ-treated MS patients.

Libertinova J, Meluzinova E, Matoska V, Zajac M, Kovarova I, Havrdova E, Horakova D, Tomek A, Marusic P, Bojar M.

Brain Behav. 2017 Feb 9;7(3):e00644. doi: 10.1002/brb3.644. eCollection 2017 Mar.

43.

Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis.

Muraro PA, Pasquini M, Atkins HL, Bowen JD, Farge D, Fassas A, Freedman MS, Georges GE, Gualandi F, Hamerschlak N, Havrdova E, Kimiskidis VK, Kozak T, Mancardi GL, Massacesi L, Moraes DA, Nash RA, Pavletic S, Ouyang J, Rovira M, Saiz A, Simoes B, Trnený M, Zhu L, Badoglio M, Zhong X, Sormani MP, Saccardi R; Multiple Sclerosis–Autologous Hematopoietic Stem Cell Transplantation (MS-AHSCT) Long-term Outcomes Study Group.

JAMA Neurol. 2017 Apr 1;74(4):459-469. doi: 10.1001/jamaneurol.2016.5867.

44.

Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.

Kalincik T, Brown JWL, Robertson N, Willis M, Scolding N, Rice CM, Wilkins A, Pearson O, Ziemssen T, Hutchinson M, McGuigan C, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, Izquierdo G, Lugaresi A, Prat A, Girard M, Duquette P, Grammond P, Alroughani R, Pucci E, Sola P, Hupperts R, Lechner-Scott J, Terzi M, Van Pesch V, Rozsa C, Grand'Maison F, Boz C, Granella F, Slee M, Spitaleri D, Olascoaga J, Bergamaschi R, Verheul F, Vucic S, McCombe P, Hodgkinson S, Sanchez-Menoyo JL, Ampapa R, Simo M, Csepany T, Ramo C, Cristiano E, Barnett M, Butzkueven H, Coles A; MSBase Study Group.

Lancet Neurol. 2017 Apr;16(4):271-281. doi: 10.1016/S1474-4422(17)30007-8. Epub 2017 Feb 11.

PMID:
28209331
45.

Survey of diagnostic and treatment practices for multiple sclerosis in Europe.

Fernández O, Delvecchio M, Edan G, Fredrikson S, Gionvannoni G, Hartung HP, Havrdova E, Kappos L, Pozzilli C, Soerensen PS, Tackenberg B, Vermersch P, Comi G.

Eur J Neurol. 2017 Mar;24(3):516-522. doi: 10.1111/ene.13236. Epub 2017 Jan 31.

PMID:
28139062
46.

Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis.

Liu Y, Vollmer T, Havrdova E, Riester K, Lee A, Phillips G, Wang P, Sabatella G.

Mult Scler Relat Disord. 2017 Jan;11:18-24. doi: 10.1016/j.msard.2016.11.005. Epub 2016 Nov 13.

47.

Myxovirus Resistance Protein A mRNA Expression Kinetics in Multiple Sclerosis Patients Treated with IFNβ.

Libertinova J, Meluzinova E, Tomek A, Horakova D, Kovarova I, Matoska V, Kumstyrova S, Zajac M, Hyncicova E, Liskova P, Houzvickova E, Martinkovic L, Bojar M, Havrdova E, Marusic P.

PLoS One. 2017 Jan 12;12(1):e0169957. doi: 10.1371/journal.pone.0169957. eCollection 2017.

48.

No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study.

Kappos L, Havrdova E, Giovannoni G, Khatri BO, Gauthier SA, Greenberg SJ, You X, Wang P, Giannattasio G.

Mult Scler. 2017 Nov;23(13):1736-1747. doi: 10.1177/1352458516683266. Epub 2016 Dec 22.

PMID:
28080250
49.

Serum lipid profile changes predict neurodegeneration in interferon-β1a-treated multiple sclerosis patients.

Uher T, Fellows K, Horakova D, Zivadinov R, Vaneckova M, Sobisek L, Tyblova M, Seidl Z, Krasensky J, Bergsland N, Weinstock-Guttman B, Havrdova E, Ramanathan M.

J Lipid Res. 2017 Feb;58(2):403-411. doi: 10.1194/jlr.M072751. Epub 2016 Dec 6.

50.

Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice.

Spelman T, Meyniel C, Rojas JI, Lugaresi A, Izquierdo G, Grand'Maison F, Boz C, Alroughani R, Havrdova E, Horakova D, Iuliano G, Duquette P, Terzi M, Grammond P, Hupperts R, Lechner-Scott J, Oreja-Guevara C, Pucci E, Verheul F, Fiol M, Van Pesch V, Cristiano E, Petersen T, Moore F, Kalincik T, Jokubaitis V, Trojano M, Butzkueven H; MSBasis (an MSBase Substudy) Investigators.

Mult Scler. 2017 Sep;23(10):1346-1357. doi: 10.1177/1352458516679893. Epub 2016 Nov 25.

PMID:
27885062

Supplemental Content

Loading ...
Support Center